内镜联合选择性环氧合酶2抑制剂治疗食管粘膜不典型性增生的临床研究  

Clinical observation of endoscopy combined with selective cyclooxygenase 2 inhibitors for esophageal atypical hyperplasia

作　　者：邓国星[1] 李荣萍[1] 云辉[1] 朱霖[1] 唐浩[2] 

机构地区：[1]解放军第187中心医院消化内科,海南海口571159 [2]解放军第187中心医院肝胆外科,海南海口571159

出　　处：《局解手术学杂志》2012年第5期518-519,522,共3页Journal of Regional Anatomy and Operative Surgery

摘　　要：目的探究内镜联合选择性环氧合酶2抑制剂治疗食管粘膜不典型性增生的安全性与有效性。方法收集临床食管粘膜不典型性增生患者63例,随机分成2组,对照组30例单纯采用内镜治疗,研究组33例在内镜治疗的基础上加用选择性环氧合酶2抑制剂;比较2组患者治疗前后的病灶情况、临床症状改善程度以及血管内皮生长因子(VEGF)的表达情况。结果经过12个月的随访,研究组治疗好转率达到75.76%,血清中的VEGF含量也得到了明显抑制,与对照组相比均具有显著的统计学差异(P<0.05)。结论内镜联合选择性环氧合酶2抑制剂治疗食管粘膜不典型性增生不仅有效而且安全。Objective To analyze the clinical effect and safety of endoscopy combined with selective cyclooxygenase 2 inhibitors for patients with esophageal atypical hyperplasia. Methods Totally 63 patients with esophageal atypical hyperplasia were studied and divided into control group （n = 30） and experiment group （n = 33 ）. Endoscopy was applied in control group while selective cyclooxygenase 2 inhibitors therapy combined with endoscopy was used in experimental group. The clinical effect, expressions of vascular endothelial growth factor （VEGF） and safety were compared between the two groups after the therapy finished. Results After 12 months, there were marked differences between the two groups in the clinical effect and the expressions of VEGF （P 〈 0.05 ）. Conclusion The therapy of endoscopy combined with selective cyclooxygenase 2 inhibitors for patients with esophageal atypical hyperplasia is effective and safe.

关 键 词：内镜 选择性环氧合酶2抑制剂 食管粘膜不典型性增生 

分 类 号：R571[医药卫生—消化系统]